376138.fig.003a
(a)
376138.fig.003b
(b)
376138.fig.003c
(c)
376138.fig.003d
(d)
376138.fig.003e
(e)
376138.fig.003f
(f)
376138.fig.003g
(g)
376138.fig.003h
(h)
376138.fig.003i
(i)
376138.fig.003j
(j)
376138.fig.003k
(k)
376138.fig.003l
(l)
376138.fig.003m
(m)
376138.fig.003n
(n)
376138.fig.003o
(o)
Figure 3: Effect of EB101 vaccine on neurofibrillary tangle-like structures in the brains of B6C3F1/J mice. Comparative photomicrographs of neurofibrillary tangle-like structure immunoreactivity taken in the hippocampus ((a), (b), (d), (e), (g), (h), (j), (k), (m), (n)) and cortical ((c), (f), (i), (l), (o)) brain regions in the preventive treatment group, ((a)–(i)) and therapeutic treatment group, ((j)–(o)). Preventive Treatment: Transverse brain sections of 11-month-old mice show almost complete prevention of neurofibrillary tangle-like structure (NFTs) formation after EB101 vaccine immunization in the hippocampal subregion CA1 (a), dentate gyrus (b), and entorhinal cortex (c) contrasting with the same regions of EB102-immunized mice ((d)–(f)) and PBS ((g)–(i)). Immunoreactive NFTs are absent in the brain sections of wild-type mice (inserts in (g)–(i)). Therapeutic Treatment: Transverse brain sections of 18-month-old mice show almost complete reduction of NFTs after EB101 vaccine immunization in the dentate gyrus (j), hippocampal subregion CA1 (k), and entorhinal cortex (l), compared with the same regions of EB102-immunized mice ((m)–(o)). Scale bar: 100 μm.